Literature DB >> 1884186

Vulnerability of nerve fibres to ischaemia. A quantitative light and electron microscope study.

H Fujimura1, C Lacroix, G Said.   

Abstract

In order to learn more about the vulnerability of nerve fibres to ischemia, a quantitative study of nerve fibre abnormalities was performed on biopsy specimens of the superficial branch of the peroneal nerve from 26 patients with vasculitic neuropathy: 20 had necrotizing arteritis, 5 a lymphocytic, and 1 a leucocytoclastic vasculitis on nerve and/or muscle biopsy. The density of myelinated fibres ranged from 25 to 7880 per mm2 (n = 8470 +/- 706 (SD]. There was a marked inequality in the density of nerve fibres between the fascicles of individual nerves with a mean coefficient of variation of 41 +/- 37 (SD) % versus 7.4 +/- 3.0% in controls. Loss of myelinated fibres, which was greater for fibres larger than 7 microns in diameter, was more severe than that for unmyelinated axons. Regeneration, which was assessed by the number of clustered axons, decreased when the density of myelinated fibres decreased, suggesting that severe nerve ischaemia precludes axonal regeneration. Wallerian degeneration affected on average 58% (range 5-100%) and segmental demyelination, mainly of the secondary type, on average 1.94% (range 1-10%) of teased fibres. It was concluded that (1) myelinated fibres are more vulnerable to ischaemia than unmyelinated axons; (2) large myelinated fibres are affected before the smaller ones; (3) segmental demyelination is uncommon in this context; (4) severe nerve ischaemia precludes axonal regeneration.

Entities:  

Mesh:

Year:  1991        PMID: 1884186     DOI: 10.1093/brain/114.4.1929

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

1.  A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse.

Authors:  L Conforti; A Tarlton; T G Mack; W Mi; E A Buckmaster; D Wagner; V H Perry; M P Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 2.  Primary and secondary vasculitic neuropathy.

Authors:  Gérard Said; Catherine Lacroix
Journal:  J Neurol       Date:  2005-04-05       Impact factor: 4.849

Review 3.  Diabetic neuropathy: an update.

Authors:  G Said
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

Review 4.  Peripheral neuropathy in polyarteritis nodosa.

Authors:  G Said
Journal:  Springer Semin Immunopathol       Date:  1996

5.  Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways.

Authors:  M M Sousa; S Du Yan; R Fernandes; A Guimaraes; D Stern; M J Saraiva
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

6.  Ultrastructural immunolabelling of amyloid fibrils in acquired and hereditary amyloid neuropathies.

Authors:  D Adams; G Said
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

7.  [A patient with Churg-Strauss syndrome presenting as Guillain-Barré syndrome].

Authors:  M Djukic; H Schmidt; C Mazurek; F König; S Schweyer; R Nau
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

8.  Familial amyloid polyneuropathy associated with transthyretin Gly42 mutation: a quantitative light and electron microscopic study of the peripheral nervous system.

Authors:  K Toyooka; H Fujimura; S Ueno; H Yoshikawa; M Kaido; T Nishimura; S Yorifuji; T Yanagihara
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

9.  Changes in the short- and long-latency stretch reflex components of the triceps surae muscle during ischaemia in man.

Authors:  S J Fellows; F Dömges; R Töpper; A F Thilmann; J Noth
Journal:  J Physiol       Date:  1993-12       Impact factor: 5.182

10.  Nerve sonography to detect peripheral nerve involvement in vasculitis syndromes.

Authors:  H Stephan Goedee; W Ludo van der Pol; Jan-Thies H van Asseldonk; Alexander F J E Vrancken; Nicolette C Notermans; Leo H Visser; Leonard H van den Berg
Journal:  Neurol Clin Pract       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.